The Impact of Clinical Prognosis of Viral Hepatitis in Head and Neck Cancer Patients Receiving Concurrent Chemoradiotherapy
This study evaluated the clinical characteristics of head and neck cancer (HNC) patients with hepatitis B (HBV) or hepatitis C (HCV) who underwent concurrent chemoradiotherapy (CCRT) and examined the prognostic impact of antiviral therapies. In a 19-year retrospective analysis of 8224 HNC patients t...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/11/2946 |
| _version_ | 1797460087423369216 |
|---|---|
| author | Yu-Ming Wang Sheng-Dean Luo Ching-Nung Wu Shao-Chun Wu Wei-Chih Chen Yao-Hsu Yang Tai-Jan Chiu |
| author_facet | Yu-Ming Wang Sheng-Dean Luo Ching-Nung Wu Shao-Chun Wu Wei-Chih Chen Yao-Hsu Yang Tai-Jan Chiu |
| author_sort | Yu-Ming Wang |
| collection | DOAJ |
| description | This study evaluated the clinical characteristics of head and neck cancer (HNC) patients with hepatitis B (HBV) or hepatitis C (HCV) who underwent concurrent chemoradiotherapy (CCRT) and examined the prognostic impact of antiviral therapies. In a 19-year retrospective analysis of 8224 HNC patients treated with CCRT, 29.8% (2452) were diagnosed with HBV or HCV, of whom 714 received antiviral therapy. For non-metastatic HNC patients on CCRT, factors such as gender, Charlson Comorbidity Index (CCI), liver cirrhosis markers (Fibrosis-4, APRI), and initial tumor stage were significant determinants of their overall survival. However, the presence of HBV or HCV and the administration of antiviral treatments did not yield distinct survival outcomes. In summary, antiviral therapy for HBV or HCV did not affect the 5-year survival rates of non-metastatic HNC patients undergoing CCRT, while gender, tumor stage, CCI, and liver cirrhosis were notable prognostic indicators. |
| first_indexed | 2024-03-09T17:01:09Z |
| format | Article |
| id | doaj.art-fd6e3f468a0e437c8f55943a66504b1e |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T17:01:09Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-fd6e3f468a0e437c8f55943a66504b1e2023-11-24T14:30:52ZengMDPI AGBiomedicines2227-90592023-11-011111294610.3390/biomedicines11112946The Impact of Clinical Prognosis of Viral Hepatitis in Head and Neck Cancer Patients Receiving Concurrent ChemoradiotherapyYu-Ming Wang0Sheng-Dean Luo1Ching-Nung Wu2Shao-Chun Wu3Wei-Chih Chen4Yao-Hsu Yang5Tai-Jan Chiu6Department of Radiation Oncology & Proton and Radiation Therapy Center, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDepartment of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDepartment of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, TaiwanGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, No. 259, Wenhua 1st Rd., Guishan District, Taoyuan 333, TaiwanDepartment of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, TaiwanSchool of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan 333, TaiwanGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, No. 259, Wenhua 1st Rd., Guishan District, Taoyuan 333, TaiwanThis study evaluated the clinical characteristics of head and neck cancer (HNC) patients with hepatitis B (HBV) or hepatitis C (HCV) who underwent concurrent chemoradiotherapy (CCRT) and examined the prognostic impact of antiviral therapies. In a 19-year retrospective analysis of 8224 HNC patients treated with CCRT, 29.8% (2452) were diagnosed with HBV or HCV, of whom 714 received antiviral therapy. For non-metastatic HNC patients on CCRT, factors such as gender, Charlson Comorbidity Index (CCI), liver cirrhosis markers (Fibrosis-4, APRI), and initial tumor stage were significant determinants of their overall survival. However, the presence of HBV or HCV and the administration of antiviral treatments did not yield distinct survival outcomes. In summary, antiviral therapy for HBV or HCV did not affect the 5-year survival rates of non-metastatic HNC patients undergoing CCRT, while gender, tumor stage, CCI, and liver cirrhosis were notable prognostic indicators.https://www.mdpi.com/2227-9059/11/11/2946head and neck cancerviral hepatitischemoradiationantiviral therapyprognosis |
| spellingShingle | Yu-Ming Wang Sheng-Dean Luo Ching-Nung Wu Shao-Chun Wu Wei-Chih Chen Yao-Hsu Yang Tai-Jan Chiu The Impact of Clinical Prognosis of Viral Hepatitis in Head and Neck Cancer Patients Receiving Concurrent Chemoradiotherapy Biomedicines head and neck cancer viral hepatitis chemoradiation antiviral therapy prognosis |
| title | The Impact of Clinical Prognosis of Viral Hepatitis in Head and Neck Cancer Patients Receiving Concurrent Chemoradiotherapy |
| title_full | The Impact of Clinical Prognosis of Viral Hepatitis in Head and Neck Cancer Patients Receiving Concurrent Chemoradiotherapy |
| title_fullStr | The Impact of Clinical Prognosis of Viral Hepatitis in Head and Neck Cancer Patients Receiving Concurrent Chemoradiotherapy |
| title_full_unstemmed | The Impact of Clinical Prognosis of Viral Hepatitis in Head and Neck Cancer Patients Receiving Concurrent Chemoradiotherapy |
| title_short | The Impact of Clinical Prognosis of Viral Hepatitis in Head and Neck Cancer Patients Receiving Concurrent Chemoradiotherapy |
| title_sort | impact of clinical prognosis of viral hepatitis in head and neck cancer patients receiving concurrent chemoradiotherapy |
| topic | head and neck cancer viral hepatitis chemoradiation antiviral therapy prognosis |
| url | https://www.mdpi.com/2227-9059/11/11/2946 |
| work_keys_str_mv | AT yumingwang theimpactofclinicalprognosisofviralhepatitisinheadandneckcancerpatientsreceivingconcurrentchemoradiotherapy AT shengdeanluo theimpactofclinicalprognosisofviralhepatitisinheadandneckcancerpatientsreceivingconcurrentchemoradiotherapy AT chingnungwu theimpactofclinicalprognosisofviralhepatitisinheadandneckcancerpatientsreceivingconcurrentchemoradiotherapy AT shaochunwu theimpactofclinicalprognosisofviralhepatitisinheadandneckcancerpatientsreceivingconcurrentchemoradiotherapy AT weichihchen theimpactofclinicalprognosisofviralhepatitisinheadandneckcancerpatientsreceivingconcurrentchemoradiotherapy AT yaohsuyang theimpactofclinicalprognosisofviralhepatitisinheadandneckcancerpatientsreceivingconcurrentchemoradiotherapy AT taijanchiu theimpactofclinicalprognosisofviralhepatitisinheadandneckcancerpatientsreceivingconcurrentchemoradiotherapy AT yumingwang impactofclinicalprognosisofviralhepatitisinheadandneckcancerpatientsreceivingconcurrentchemoradiotherapy AT shengdeanluo impactofclinicalprognosisofviralhepatitisinheadandneckcancerpatientsreceivingconcurrentchemoradiotherapy AT chingnungwu impactofclinicalprognosisofviralhepatitisinheadandneckcancerpatientsreceivingconcurrentchemoradiotherapy AT shaochunwu impactofclinicalprognosisofviralhepatitisinheadandneckcancerpatientsreceivingconcurrentchemoradiotherapy AT weichihchen impactofclinicalprognosisofviralhepatitisinheadandneckcancerpatientsreceivingconcurrentchemoradiotherapy AT yaohsuyang impactofclinicalprognosisofviralhepatitisinheadandneckcancerpatientsreceivingconcurrentchemoradiotherapy AT taijanchiu impactofclinicalprognosisofviralhepatitisinheadandneckcancerpatientsreceivingconcurrentchemoradiotherapy |